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Carcinoid lung tumors: long-term results from 111
resections
Langzeitergebnisse nach 111 Resektionen wegen Bronchuskarzinoid
Abstract
Objective: Carcinoids are rare neuroendocrine tumors of the bronchial
system. Only recently, the histological classification was standardized,
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and there are varying opinions about the extent of surgical resection.
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This research reports on the long-term results of 111 consecutive pa-
tients, who underwent surgery in a department for thoracic surgery. Peter Fritz
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Methods: Between 1/1988 and 2/2001, 111 consecutive pulmonary
resections were conducted in patients with bronchial carcinoids. Retro- Heikki Toomes
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spectively, researchers obtained clinical and surgical data and re-clas-
sified all histological specimen according to the WHO classification of
1999. Information regarding long-term results was obtained by using 1 Department of Thoracic
Surgery, Center for data obtained during follow-up visits and by talking to the patient on
the phone. Pneumology and Thoracic
Results: 97 patients with typical and 14 with atypical carcinoids were
identified. The preoperative diagnosis of typical or atypical carcinoid
Surgery, Schillerhoehe
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had been correct in 56 patients (50.5%). Surgical procedures included 2 Center for Pathology, Robert
Bosch Hospital, Stuttgart,
Germany
79 lobectomies, 16 bilobectomies, 8 pneumonectomies, 5 segmental
resections, 2 sleeve resections of the main bronchus without paren-
chymal resection and one exploratory thoracotomy. Mediastinal
lymphadenectomies were performed on 105 patients (94.6%).
Post-operative staging revealed 91 patients (81.2%) in UICC stage I, 12
(10.8%) in stage II, 7 in stage III and one in stage IV. 97 (87.4%) typical
and 14 (12.6%) atypical carcinoids were classified. 30-day mortality
was 1.8% (n=2). Mean follow-up was 73.4 months. The total cohort
showed a 5-year survival rate of 94% and a 10-year survival rate of
82%.Inpatientswithtypicalandatypicalcarcinoids,the5-yearsurvival
rates were 94% and 82%, respectively (n.s.), and the 10-year survival
rates were 92% and 62%, respectively (p<0.01). The 5- (10-) year sur-
vival rate without lymph node involvement was 96% (85%), with N1 in-
volvement 88% (65%), with N2 involvement 67% (no 10-year survival).
Conclusions:Patientswithbronchialcarcinoidswhounderwentaradical
oncological resection with mediastinal lymphadenectomy have very
good survival chances. There are no prospective randomized studies
evaluating the surgical procedures as they relate to the classification.
Since a preoperative diagnosis cannot clearly determine if the lymph
nodes are involved and what histology type the physician dealing with,
alimitedresectionswithoutlymphadenectomyisinsufficient.Itisabso-
lutely necessary to conduct retrospective and multi-center studies on
theprognosticimportanceoflymphnodeinvolvementandontheimpact
of adjuvant therapies.
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Zusammenfassung
Fragestellung: Das Karzinoid zählt zu den seltenen neuroendokrinen
Tumoren des Bronchialsystems. Die histologische Klassifikation wurde
erst jüngst vereinheitlicht, und über das Ausmaß der chirurgischen Re-
sektion existieren unterschiedliche Ansichten. Wir berichten über den
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Research Article OPEN ACCESSLangzeitverlaufvon111konsekutivenPatientendieineinerthoraxchir-
urgischen Abteilung operiert wurden.
Patienten und Methode: Von 1/1988 bis 2/2001 erfolgten 111 Lun-
genresektionen wegen Bronchuskarzinoid. Retrospektiv wurden ana-
mnestische, klinische und operationsbezogene Daten erhoben. Die
histologischen Präparate aller operierten Patienten mit der Diagnose
„Bronchuskarzinoid“wurdenüberprüftundnachdenKriterienderWHO
Klassifikation von 1999 reklassifiziert. Angaben zum Langzeitverlauf
wurden durch Tumornachsorgedokumentation und telefonische Befra-
gung 8/2004 erfasst.
Ergebnisse: 97 typische und 14 atypische Karzinoide wurden klassifi-
ziert. Die Diagnose „Karzinoid“ und der Differenzierungsgrad waren
präoperativbei56Patienten(50,5%)richtigfestgelegtworden.Operiert
wurden: 79 Lobektomien, 16 Bilobektomien, 8 Pneumonektomien, 5
Segmentresektionen, 2 Manschettenresektionen des Hauptbronchus
ohne Parenchymresektion und eine Probethorakotomie. Mediastinale
Lymphadenektomienerfolgtenbei105Patienten(94,6%).Diepostope-
rative Stadieneinteilung ergab: 91 x (81,2%) UICC Stadium I, 12 x
(10,8%) Stadium II, 7 x Stadium III und einmal Stadium IV. 97 (87,4%)
typische und 14 (12,6%) atypische Karzinoide wurden klassifiziert. Die
30-Tage-Mortalitätbetrug1,8%(n=2).DerNachbeobachtungszeitraum
betrug im Durchschnitt 73,4 Monate. Für die gesamte Kohorte wurde
ein 5-Jahresüberleben von 94% und ein 10-Jahresüberleben von 82%
ermittelt;beiPatientenmittypischembzw.atypischemKarzinoidwaren
es nach 5 Jahren 94% bzw. 82% (n.s.) und nach 10 Jahren 92% bzw.
62% (p<0,01). Das 5- (10-) Jahresüberleben ohne Lymphknotenbefall
(N0) betrug 96% (85%), bei N1 Befall 88% (65%), bei N2 Befall 67%
(10-Jahresüberleben nicht erreicht).
Folgerungen: Nach onkologisch radikaler Resektion mit mediastinaler
Lymphadenektomie haben Patienten mit Bronchuskarzinoid eine sehr
gutePrognose.ProspektivrandomisierteUntersuchungenzurEvaluation
verschiedener Operationsverfahren in Abhängigkeit vom Differenzie-
rungsgradexistierennicht.WeildiepräoperativeDiagnostiknichtsicher
Lymphknotenbefall und ungünstigeren Histologietyp ermitteln kann,
halten wir limitierte Resektionen ohne Lymphadenektomie nicht für
ausreichend. Prospektive und multizentrische Untersuchungen zur
prognostischen Bedeutung des Lymphknotenbefalls und zum Wert ad-
juvanter Therapien sind unumgänglich.
Introduction
Bronchial carcinoids are rare neuroendocrine tumors;
age-adjusted incidences are between 0.38/100,000 for
men and 0.49/100,000 for women [1]. According to the
current WHO classification, the bronchial carcinoid is
classified as a neuroendocrine lung tumor, as are the
smallcellbronchialcarcinomaandthelargecellneuroen-
docrine bronchial carcinoma [2], [3]. Typical and atypical
carcinoids are a subgroup of this segment; criteria to
differentiate between the typical and atypical carcinoid
and small cell neuroendocrine bronchial carcinoma are
defined in a very precise manner [3], [4]. The classifica-
tion takes into account the different prognoses for
neuroendocrine lung tumors, as survival rates differ sig-
nificantly between typical and atypical carcinoids, and
betweenatypicalcarcinoidandlargecellneuroendocrine
bronchial carcinoma [2].
The prognoses for bronchial carcinoids are reported to
be very good, particularly after surgical resection [1], [5],
[6],[7],[8],[9],[10],[11].SinceitsdescriptionbyArrigoni,
the atypical carcinoid is regarded as a variation with a
less favorable prognosis [2], [12]. During the past two
decades, surgical interest has mainly focused on the
question whether less radical resections are adequate
fortheprognosticallyfavorabletypicalcarcinoidcompared
to the atypical form. This question is still the subject of
many controversial discussions [1], [5], [6], [7], [9], [10],
[13],[14],[15].Furthermore,itisnotclearwhetherlymph
node involvement can be recognized as an independent
prognostic factor [5], [7], [9], [11], [16], [17], [18]. In
addition,thereisnoclearconsensusonwhetheraradical
mediastinal lymphadenectomy should be recommended
[5], [15], [18]. There is no information regarding the
usefulnessofadjuvanttherapiesduringadvancedtumor
stages [15], [16], [17], [19].
Thisretrospectiveanalysisanalyzesthelong-termresults
of patients who have undergone curative surgery for a
bronchial carcinoid. After the histological specimen had
been classified according to the WHO classification of
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“atypical” group [3]. We compared our own findings with
recent relevant publications in detail.
Patients and methods
Between1/1988and2/2001,124consecutivepatients
underwent therapy for a bronchial carcinoid. Because of
confirmed distant metastases or poor general health, 7
patients were unable to undergo surgical therapy, but
had a palliative endobronchial laser resection instead.
Oneoftheresearchers(S.M.)checkedtheparaffinblocks
of the remaining 117 patients who had been diagnosed
with“bronchialcarcinoid”andwhohadundergonesurgery
during the period of this study and re-classified them ac-
cording to the criteria of the WHO classification of 1999
[3].Thedataof6patientswithneuroendocrinenon-small
cell bronchial carcinoma was excluded from further ana-
lysis. Staging of the 111 remaining confirmed cases of
bronchial carcinoids was conducted in accordance with
the TNM classification of 2002 for non-small cell lung
cancer.
Follow-up in our department was conducted 2-4 times
per year with annual bronchoscopic testing until the 5th
postoperativeyear.Patientinformationforthetimeperiod
after the conclusion of the follow-up visits was obtained
calling the patients themselves or their family physicians
in 8/2004.
Survival and recurrence rates were calculated by using
theKaplan-Meiermethod,differencesinsurvivalbyusing
the log-rank test. The study was approved by the ethics
committee on human research of the University of
Tubingen/Germany.
Results
59 men and 52 women between the ages of 16 and 78
(median 51 years) underwent surgery. The median age
of patients with atypical carcinoids was higher than that
of patients with typical carcinoids (55 vs. 51 years, n.s.).
Preoperatively, 71.2% (n=79) of all patients had clinical
symptoms:cough(n=33,29.7%),dyspnea(n=14,12.6%),
pneumonia (n=14, 12.6%), fever (n=12, 10.8%), chest
pain (n=10, 9%), hemoptysis (n=7, 6.3%), and recurrent
pneumonias(n=3,2.7%).OnepatienthadincreasedACTH
production, and in one case, the carcinoid occurred
within the context of a MEN I syndrome; there were no
clinicalsignsforincreasedserotoninproduction.In28.8%
of patients (n=32) the tumor was an incidental finding
on chest X-ray. 47 patients (42.3%) were smokers; me-
dian cigarette consumption was 15 pack years (range
1-100).Thepercentageofsmokerswashigherinpatients
withatypicalcarcinoids(57.1%)thaninthosewithtypical
carcinoids (40.2%).
PreoperativediagnosticsincludedthoracicCTsforall111
patients, bronchoscopy for 110 patients, sonography or
abdominal CT for 82 patients, skeletal scintigraphy for
70 patients, cranial CT or MRI for 25 patients, and medi-
astinoscopy for 2 patients who preoperatively were sus-
pected to have a small-cell bronchial carcinoma. Due to
the risk of tumor cell dissemination, transthoracic small
needleaspirationwasnotperformedinsurgicalpatients.
Preoperative pulmonary function testing was conducted
for 110/111 patients by doing a whole body plethysmo-
graphy. 67 tumors (60.4%) were in a central location, i.e.
they were visible on the bronchoscopy. In 56 patients
(50.5%), the preoperative diagnosis “carcinoid” and the
attribution “typical” or “atypical” were confirmed by the
postoperativeresults.2patientshadpreoperativelybeen
diagnosed with a small-cell bronchial carcinoma, and 6
patients had been diagnosed with a non-small cell bron-
chial carcinoma (7.2%); both patients with suspected
small-cell bronchial carcinoma underwent preoperative
chemotherapy.
Thesurgicalproceduresperformedconsistedof79(71%)
lobectomies (2 of them with bronchial sleeve resection),
16 (14%) bilobectomies, 8 (7.2%) pneumonectomies, 5
(4.5%) segmental resections, 2 sleeve resections of the
main bronchus without parenchymal resection and one
explorative thoracotomy (termination due to pleural car-
cinosis).Mediastinallymphadenectomieswereperformed
in 105 patients (94.6%). 18 patients suffered from post-
operativecomplications(16.2%),withthefollowingsevere
complications: bleeding in 4 patients, pneumothorax in
3 patients, fatal right heart failure in 2 patients (1.8%)
and one bronchial stump insufficiency.
Histopathological follow-up revealed 97 (87.4%) typical
(TC) and 14 (12.6%) atypical carcinoids (AC) with 91
(81.2%) patients in stage I, 12 (10.8%) in stage II, 7
(6.3%)instageIIIandoneinstageIV.12patients(10.8%)
hadlymphnodeinvolvementinN1orN2positions(Table
1).
10 patients with typical carcinoids had lymph node in-
volvement (9.7%), 5 of them with ipsilateral hilar (N1)
and 5 with mediastinal lymph node metastases (N2). 3
patients with atypical carcinoid proved to have lymph
nodeinvolvement(21.4%),2ofthemwithipsilateralhilar
(N1) and 1 with mediastinal (N2) nodal deposits. In 5
patientswithmediastinallymphnodeinvolvement(pN2),
the mediastinal lymph drainage was postoperatively ir-
radiated with 60 Gy percutaneously; three of these pa-
tients had no recurrence, two patients had distant meta-
stases, and one patient died.
Mean follow-up was 73.4 months. 11 patients of the
study cohort died, 2 of them postoperatively; 4 deaths
were tumor-related, 5 not tumor-related. 11 patients
suffered recurrences: local (n=1, AC), liver metastases
(n=4, 2 TC/2 AC), multiple metastases (n=2, TC), bone
metastases (n=1, TC), and pulmonary metastases (n=1,
TC).7patientsunderwentlimitedorparenchymalsparing
resections (5 segmental resections and 2 sleeve resec-
tions of the main bronchus without parenchymal resec-
tions, 2 sleeve lobectomies); none of these patients had
local recurrences or distant metastases. The 5-year sur-
vival rate for the entire group was 94% and the 10-year
survival rate was 82%. In patients with typical carcinoid,
3/8 GMS Thoracic Surgical Science 2006, Vol. 3, ISSN 1862-4006
Kyriss et al.: Carcinoid lung tumors: long-term results from 111 ...Table 1: Postsurgical staging
5-and10-yearsurvivalrateswere94%and82%,respect-
ively,andinatypicalcarcinoid92%and62%,respectively
(5-year survival n. s., 10-year survival p<0.01). 5- (10-)
year survival without lymph node involvement was 95%
(85%), with N1 involvement 88% (65%), with N2 involve-
ment 67% (no 10-year survival). Although patients with
lymph node involvement tended to have worse results,
differenceswerenotstatisticallysignificantinaunivariate
Cox regression analysis.
Discussion
The revised WHO classification of 1999 clearly places
bronchialcarcinoidsamongtheneuroendocrinepulmon-
ary tumors; the spectrum ranges from typical carcinoids
with low-grade malignancy and atypical carcinoids with
moderatemalignancytohighlymalignantneuroendocrine
pulmonary tumors, i.e. the large cell neuroendocrine
carcinomaandsmallcellbronchialcarcinoma.Incontrast
to the 1981 classification, the differentiating criteria are
precisely defined: typical carcinoids have less than 2 mi-
tosespermm²andnotumornecroses.Iftumornecroses
or 2-10 mitoses per mm² are visible, the carcinoid is
atypical, and the large cell neuroendocrine carcinoma is
characterized by more than 10 mitoses per mm² [3].
These criteria help identify the large cell neuroendocrine
carcinoma, a kind of tumor which undoubtedly has been
included in several earlier studies on bronchial carcin-
omas [3], [11]. For this reason, all histological specimen
were re-classified – similarly to the approach chosen by
other authors – to exclude all other neuroendocrine tu-
mors [9], [11].
Epidemiology
The two histologically different tumor entities described
by the term bronchial carcinoid possibly differ in terms
of epidemiology as well. Several studies have addressed
thequestionwhetherthediseaseoccursmorefrequently
in men or in women. Although some authors report that
the disease occurs more frequently in women [1], [6],
[8], our group and other researchers were not able to
determine any differences between men and women [7],
[9], [13]. Patients with bronchial carcinoids are on aver-
age 10 years younger than patients with other malignant
pulmonary tumors [1]. 42.3% of our patients were
smokers. Whether smoking has an impact on the devel-
opmentofabronchialcarcinoid,hasyettobedetermined
[5], [6], [7], [9], [13]. According to the results of other in-
vestigators, the atypical carcinoid was found more fre-
quently in smokers than in patients with the typical car-
cinoid [7], [8], [9], [13].
Diagnosis
Thehistologicalresultsofthepreoperativebronchoscopy
is of utmost importance for therapeutic decisions [9],
[15].Accordingtosomeauthors,theextentofpulmonary
resectionandsometimestheextentofthelymphadenec-
tomy is dependent on whether the patient has a typical
or an atypical carcinoid (Table 2) [6], [7], [9], [10], [15].
Our own results have shown that it may be difficult to
preoperatively confirm the diagnosis or to differentiate
betweenthetwotypesofcarcinoid.Onlyin50.5%(n=56)
of the patients, preoperative bronchoscopy resulted in
the same classification as the postoperative analysis; in
7.2%ofthecases,asmallcellornon-smallcellcarcinoma
wasdiagnosedpreoperatively.Thepreoperativelycorrect
histologies reported in the literature range between 47%
and83%[7],[8],[9],[10],[13],[15].Surgicalapproaches
selected with regard to the different prognoses of typical
and atypical carcinoids require clear-cut criteria of differ-
entiation. However, the reproducibility of differentiation
betweentypicalandatypicalcarcinoidsbythepathologist
hasrepeatedlybeenquestioned[6],[8],[13].Thisisdue
to the fact that the criteria of differentiation are not ap-
plied as stringently as necessary [2], [20]; in addition,
the characteristic mitosis rate and tumor necrosis in
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Table 3: Long-term survival after resection of bronchial carcinoid in the literature
smaller specimen cannot always be determined [10],
[13], [15].
Prognosis
In general, the prognosis after surgery on the localized
bronchial carcinoid is considered to be very good [1], [5],
[6], [7], [8], [9], [10], [11], [18], [21]. Even metastatic
non-operated bronchial carcinoids are reported to have
a 5-year survival rate of 76.6% [1]. The only recognized
independent prognostic factors at present are the classi-
fication typical or atypical and, to a lesser extent, the
nodal status (Table 3) [6], [9].
When separately considering the course of disease for
patientswithtypicalandatypicalcarcinoids,theoutcome
forpatientswithanatypicalcarcinoidisonlyslightlyworse
after5years,butsignificantlyworseafter10years.Thus,
ourfiguressupporttheassumptionthattheclassification
of the bronchial carcinoid is a prognostic factor [2], [5],
[6], [7], [8], [9], [12]. All considerations of independent
prognostic factors are of limited value, however, due to
the low number of recurrences in the collectives with
bronchial carcinoids, which is also true for the present
study [6].
Lymph nodes
It has not been ascertained if lymph node involvement
canbeconsideredanindependentprognosticfactor.Only
a few authors have studied the prognostic importance of
lymph node involvement (Table 4) [5], [7], [9], [11], [16],
[17], [22].
This study found some evidence for a statistical correl-
ation between lymph node involvement and an unfavor-
able prognosis, which, however, might also be due to the
low number of patients with lymph node involvement.
Filossodidnotfindanimpactoflymphnodeinvolvement
on the prognosis, and neither did Schreurs, who studied
93 patients with exclusive typical carcinoids [7], [22].
However, Garcia (the Spanish multicenter study) and
Filossofoundsignificantdifferencesbetweenlymphnode
involvement in typical and atypical carcinoids [7], [16].
Mezetti revealed lower survival rates in cases with lymph
node involvement for both types of carcinoids. Independ-
ent of the histological type, McCaughan and Mezzetti
found reduced disease-free intervals in patients with
lymph node involvement [9], [18]. Cardillo reported on a
significantly lower 5-year survival rate in patients with
atypical carcinoid and N1 involvement than in patients
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with the typical carcinoid and N1 involvement; even the
5-year survival rate of patients with an atypical tumor
type and N2 involvement was significantly lower in this
study[5].Thefactthatnoteverypatenthadamediastinal
lymphadenectomycomplicatestheanalysisofthepresent
results [5]. In order to guarantee an exact staging and
adequate tumor management, it is necessary to perform
a radical or systemic lymph node dissection on a routine
basis independent of the degree of resection [5], [15],
[18]. So far, there are only retrospective studies that
evaluatetheprognosticimportanceoflymphnodeinvolve-
ment in bronchial carcinoids.
Resection procedures
Numerousauthorshaveaddressedtheextentofresection
forpatientwithacarcinoid[1],[5],[6],[7],[9],[10],[13],
[14],[15].Becauseoftheverygoodprognosis,especially
forcaseswithatypicalcarcinoids,limitedorparenchymal-
sparing resections are generally considered sufficient,
and it is particularly important to avoid unnecessary
pneumonectomies [1], [6], [7], [9], [10], [13], [14], [15].
There are only retrospective analyses of patient cohorts,
who were operated upon within long periods between 12
and 26 years, and it is not clear which criteria were ap-
plied to decide in favor of parenchymal sparing or ana-
tomicalresection[7],[13].Marty-Anecorrectlystatesthat
some authors who recommend limited resections have
mainly performed extended anatomical resections on
theirpatients,whichmighthavebeenthedecidingfactor
for their good results [13], [15]. In addition, recurrences
have sometimes been attributed only to the histological
type and the nodal status, but not to the resection pro-
cedure[7],ortherewasnomeaningfulstatisticalanalysis
duetolowrecurrencerates[7].Anotherfactorcomplicat-
ing matters is that authors differ on how they define the
terms“parenchymalsparing”or“limitedresection”(Table
2).
The patients of the present study underwent anatomical
resections such as lobectomies, bilobectomies or pneu-
monectomiesaccordingtothesamecriteriaofoncological
radicality as in non-small cell bronchial carcinoma. We
did not use this approach in 5 cases with restricted pul-
monary function and did segmental resections instead,
and in 2 patients with a typical carcinoid, we conducted
sleeve resections of the main bronchus without a paren-
chymal resection; none of these 7 patients suffered a
recurrence. Although the results reported in literature
suggest parenchymal sparing resections for confirmed
typical carcinoids, we adhered to the recommendations
of those authors who, independent of the histological
subtype and given a sufficient functional reserve, prefer
anatomical resections with radical lymphadenectomy
becauseoftheunclearpre-andintraoperativedifferenti-
ationandaseamlesstransitionsbetweenneuroendocrine
carcinomas of different malignancies [5], [11], [18].
Adjuvant therapy
5 patients who participated in this study and who had
mediastinal lymph node involvement (pN2) underwent
postoperativepercutaneousradiationtherapywith60Gy
atthemediastinallymphdrainage;threeofthesepatients
had no recurrence, two patients had distant metastases
and one patient died. In some reports on the use of ad-
juvant radiation therapy for bronchial carcinoids a total
between 2 and 9 patients had postoperative radiation
therapy, mostly because of mediastinal lymph node in-
volvement [15], [16], [17], [19]. In our opinion, the low
number of cases and recurrences do not allow for a
statement on adjuvant radiation therapy. There is no in-
formation on neoadjuvant studies or therapy protocols
in the literature. Since bronchial carcinoids may over-ex-
press somatostatin receptors, they may be treated or in-
vestigatedwithsomatostatinanalogues(e.g.octreotide).
Treatment with octreotide has so far been restricted to
advancedtumorstageswithdistantmetastases[7],[23].
So far, there are no results from controlled studies on
theapplicationofsomatostatinanaloguesasanadjuvant
in surgical therapy of bronchial carcinoids. Prospective
multicenter studies are needed to evaluate adjuvant
therapies [15], [19].
Conclusion
Due to their excellent prognoses, bronchial carcinoids
have a distinct place among the neuroendocrine tumors
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carcinoids distinguishes between two tumor entities,
which are different in terms of prognosis. Based on the
currentdata,itisnotpossibletoascertainwhetherlimited
resections depending on the histological subtype can be
recommended,whetherthenodalstatusisanindepend-
ent prognostic factor and which benefits adjuvant ther-
apiesmayhave.Thelowincidenceofbronchialcarcinoids
makes multi-centre studies indispensable. Since there
can be a seamless transition from one neuroendocrine
pulmonary tumor to another with a different prognosis
and since preoperative diagnosis is unable to exclude
lymphnodeinvolvementandunfavorabletypeofhistology
inallcases,weconsiderlimitedresectionswithoutlymph
node resection as insufficient.
Dedication
In honour of Prof. Dr. Heikki Toomes on the occasion of
his 65th anniversary.
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